Out-licensing

Messenger Biopharma will not develop its own mRNA products.

We are eager to out-license our Aegis biotechnology to pharmaceutical and biotech companies for vaccine and gene therapy products development.

Last news

our-mrna-platform-page

Messenger Biopharma in Lyonbiopole’s newsletter

posted December 22, 2016

  Please click on this ...Read More